ABVC BioPharma, Inc.
ABVC
Price:
$0.6867
Market Cap:
$8.53M
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression ...[Read more]
Industry
Biotechnology
IPO Date
2004-11-10
Stock Exchange
NASDAQ
Ticker
ABVC
The ROE as of September 2024 (TTM) for ABVC BioPharma, Inc. (ABVC) is -132.83%
According to ABVC BioPharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -132.83%. This represents a change of 299.76% compared to the average of -33.23% of the last 4 quarters.
ABVC BioPharma, Inc. (ABVC) Historical ROE (quarterly & annually)
How has ABVC ROE performed in the past?
The mean historical ROE of ABVC BioPharma, Inc. over the last ten years is -256.04%. The current -132.83% ROE has changed -48.12% with respect to the historical average. Over the past ten years (40 quarters), ABVC's ROE was at its highest in in the September 2016 quarter at 4.84%. The ROE was at its lowest in in the September 2019 quarter at -182.43%.
Average
-256.04%
Median
-127.53%
Minimum
-3730.94%
Maximum
2.61%
ABVC BioPharma, Inc. (ABVC) ROE by Quarter and Year
Discovering the peaks and valleys of ABVC BioPharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 48.37%
Maximum Annual ROE = 2.61%
Minimum Annual Increase = -123.36%
Minimum Annual ROE = -3730.94%
| Year | ROE | Change |
|---|---|---|
| 2023 | -118.96% | -77.40% |
| 2022 | -526.45% | 286.82% |
| 2021 | -136.10% | -55.83% |
| 2020 | -308.10% | -111.83% |
| 2019 | 2.61% | 3.55% |
| 2018 | 71.33% | -123.36% |
| 2017 | -305.32% | -91.82% |
| 2016 | -3730.94% | 3.26% |
| 2015 | -111.02% | 48.37% |
| 2014 | -0.23% | -101.90% |
ABVC BioPharma, Inc. (ABVC) Average ROE
How has ABVC ROE performed in the past?
The current ROE of ABVC BioPharma, Inc. (ABVC) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-260.50%
5-year avg
303.16%
10-year avg
-256.04%
ABVC BioPharma, Inc. (ABVC) ROE vs. Peers
How is ABVC’s ROE compared to its peers?
ABVC BioPharma, Inc.’s ROE is greater than Indaptus Therapeutics, Inc. (-146.70%), greater than Pasithea Therapeutics Corp. (-74.63%), less than Better Therapeutics, Inc. (223.92%), greater than Forte Biosciences, Inc. (-117.85%), less than Evelo Biosciences, Inc. (176.03%), greater than Aptinyx Inc. (-31.15%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Aridis Pharmaceuticals, Inc. (-21.32%), less than Akari Therapeutics, Plc (1.04%), greater than Aditxt, Inc. (-607.01%), greater than Acasti Pharma Inc. (-18.84%), greater than RenovoRx, Inc. (-403.38%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Monopar Therapeutics Inc. (-110.60%), greater than Eledon Pharmaceuticals, Inc. (-124.74%), greater than Nutriband Inc. (-76.31%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Longeveron Inc. (-246.98%), greater than Virax Biolabs Group Limited (-115.10%),
| Company | ROE | Market cap |
|---|---|---|
| -146.70% | $15.30M | |
| -74.63% | $4.04M | |
| 223.92% | $5.45K | |
| -117.85% | $10.70M | |
| 176.03% | $1.90K | |
| -31.15% | $4.13M | |
| -61.71% | $42.44M | |
| -47.94% | $61.75M | |
| -21.32% | $44.57K | |
| 1.04% | $41.66M | |
| -607.01% | $2.55M | |
| -18.84% | $26.25M | |
| -403.38% | $26.15M | |
| -122.97% | $54.20M | |
| -94.04% | $25.75M | |
| -110.60% | $15.00M | |
| -124.74% | $104.69M | |
| -76.31% | $52.04M | |
| -112.11% | $2.51M | |
| -246.98% | $29.70M | |
| -115.10% | $12.42M |
Build a custom stock screener for ABVC BioPharma, Inc. (ABVC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ABVC BioPharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ABVC BioPharma, Inc. (ABVC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ABVC BioPharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ABVC BioPharma, Inc.'s ROE?
How is the ROE calculated for ABVC BioPharma, Inc. (ABVC)?
What is the highest ROE for ABVC BioPharma, Inc. (ABVC)?
What is the 3-year average ROE for ABVC BioPharma, Inc. (ABVC)?
What is the 5-year average ROE for ABVC BioPharma, Inc. (ABVC)?
How does the current ROE for ABVC BioPharma, Inc. (ABVC) compare to its historical average?